.png)
Michael Cherny sees opportunity for Hims & Hers (HIMS), as long as it can overcome headwinds facing its non-weight loss businesses. He argues the stock hasn't traded on fundamentals and weighs heavily on its GLP-1 drugs sales. As for the company's partnership with Novo Nordisk (NVO), he says it was "so short-term" that Hims didn't benefit from it.
======== Schwab Network ========
Empowering every investor and trader, every market day.
Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe
Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185
Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7
Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch
Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore
Watch on DistroTV - https://www.distro.tv/live/schwab-network/
Follow us on X – https://twitter.com/schwabnetwork
Follow us on Facebook – https://www.facebook.com/schwabnetwork
Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/
About Schwab Network - https://schwabnetwork.com/about
#hims #nvo #earnings #economy #finance #investing #marketnews #stock #stockmarket #trading #live #schwabnetwork #himsandhers #glp1 #weightloss #healthcare #novonordisk
